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Triage of women with ASC-US/LSIL cytology:   
The added value of implementation of an HPV-test 
Background 
Within the Norwegian cervical cancer screening program women were recommended biopsy after three 
consecutive smears of minor lesions (ASC-US/LSIL) 6-12 months apart until 2005. In 2005 the 
recommendations for biopsy changed to the 2nd ASC-US/LSIL, if the HPV-test was positive.  
Objective 
To determine the outcomes of secondary cervical cancer screening in two time-periods before (1996-1998) 
and after (2006-2008) implementation of an HPV test 
 
 
In triage of women with ASC-US/LSIL, the HPV mRNA 
test significantly reduced the time from the first abnormal 
cytology until biopsy and had predictive values 
comparable with those of repeat cytology 
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Figure 1. Flow-chart indicating the guidelines for follow-ups during first study period 1996 – 1998.
Figure 2. Flow-chart indicating the guidelines for follow-ups during second study 
period 2006 – 2008. (Source: Sørbye SW et al. 2010)
Materials and methods 
 
This study has an historical prospective design by 
including in retrospect all screening- and follow-up tests 
for women aged 25 to 69 years old kept by the 
Department of Clinical Pathology, University Hospital of 
Northern Norway, Tromsø.  
 
All women with a first ASC-US/LSIL smear in 1996-98 
and 2006-08 were identified and compared on 
outcomes such as proportion of cases resolved within 
35 months of index smear and incidence of CIN2+.   
 
The Department of Clinical pathology has used an 
mRNA test (NorChip PreTect HPV-Proofer) since the 
autumn of 2005 in secondary cervical cancer screening. 
Results 
• In 1996-98 and 2006-08 our laboratory 
processed 89 781 and 70 433 smears, 
respectively, in which periods 1733 and 1148 
first diagnosis ever of ASC-US/LSIL were 
diagnosed among women 25 through 69 years 
of age.  
 
• In 2006-08 744 of 1148 eligible women had a 
valid HPV-test and comprise the study 
population in this study period.  
 
• In these subsets 14.6% (253/1733) in 1996-98 
and 10.4% (77/744) in 2006-08 of the women 
were eligible for colposcopy/biopsy according 
to national screening recommendations. 
 
• In 2006-08, when the HPV mRNA test was 
applied, the mean time to resolve an ASC-
US/LSIL was 12 months (range 1-39) relative 
24 months (range 1-146) in 1996-98 (p<0,01).  
 
• There were no differences in the biopsy rate in 
women recommended colposcopy (49.4% 
versus 53.2%), nor the positive predictive 
value of CIN2+ 67.2% (84/124) versus 68.3% 
(28/41) over the time-periods. 
 
Study period Number of cases Average time taken to biopsy 
1996 – 1998 125 24 (23,8 ≈ 24) Months 
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